e-learning
resources
Amsterdam 2011
Monday, 26.09.2011
Tuberculosis in immunocompromised hosts
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Negative predictive value of TST and IGRA in anti-TNF treated patients
S. Campainha, T. Gomes, A. Carvalho, R. Duarte (Vila Nova de Gaia, Vila Real, Portugal)
Source:
Annual Congress 2011 - Tuberculosis in immunocompromised hosts
Session:
Tuberculosis in immunocompromised hosts
Session type:
Poster Discussion
Number:
1942
Disease area:
Respiratory infections
Abstract
Background:
Anti-TNF therapy is increasingly used in chronic inflammatory diseases. As it is related to increased risk of tuberculosis (TB), screening is mandatory before starting on anti-TNF. Negative predictive value (NPV) of tuberculin skin test (TST) and interferon gamma assay(IGRA) are still not well defined in these patients.
Aim:
Determination of TST and IGRA NPV for progression to disease in patients on anti-TNF therapy.
Methods:
Retrospective analysis of anti-TNF candidates screened for TB between Jan-2008 and Jun-2010. Screening included symptom inquiry, chest radiograph, TST and IGRA. After active TB exclusion, all who tested positive TST or IGRA or had radiological evidence of past non-treated TB or recent contact with TB started preventive therapy (PT).
Follow-up
maintained until Jan-2011. Evaluation of NPV on patients who did not start PT.
Results:
We evaluated 158 patients. Mean age: 42.8±12,6 years; 81 males. Most frequent co-morbidities: psoriasis (34%), inflammatory bowel diseases (26%) and rheumatoid arthritis (16,4%). At screening 85 patients (53,8%) were on immunosuppressant drugs,mostly steroids; 8 were on anti-TNF.
None of the patients who started PT developed active TB.
Forty-five immunocompetent and 24 immunocompromised patients negative for TST and IGRA did not do PT and started anti-TNF. One immunocompromised patients developed active TB, 22 months after etanercept initiation.
A NPV for progression to disease (for TST and IGRA) of 95,8% in immunocompromised, and 100% in immunocompetent patients was defined.
Discussion
: NPV of available TB screening tests is higher in immunocompetents. TB screening should be advised in an early stage of disease before starting any immunosuppressant drugs.
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Campainha, T. Gomes, A. Carvalho, R. Duarte (Vila Nova de Gaia, Vila Real, Portugal). Negative predictive value of TST and IGRA in anti-TNF treated patients. Eur Respir J 2011; 38: Suppl. 55, 1942
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Persistent fever and cytopenia in a patient with pulmonary tuberculosis
CARDIAC DYSFUNCTION IN ACTIVE PULMONARY TUBERCULOSIS: DOUBLE TROUBLE!!
Whole genome sequencing of the highly virulent subtype B0/W148 of the Beijing genotype M.tuberculosis in Kharkiv, East Ukraine
Related content which might interest you:
Negative predictive value of TST and IGRA in anti-TNF treated patients},
Source: Eur Respir J 2012; 40: 790-791
Year: 2012
IGRA and TST predictive value in immunocompetent close contacts
Source: Annual Congress 2011 - Tuberculin skin tests, interferon-gamma release assays and beyond
Year: 2011
Predictive value of a whole-blood IGRA for the development of active TB disease
Source: Annual Congress 2008 - Interferon-gamma methods for the diagnosis of tuberculosis infection and disease
Year: 2008
Predictive value for progression to tuberculosis by IGRA and TST in immigrant contacts
Source: Eur Respir J 2010; 35: 1346-1353
Year: 2010
Frequency and significance of indeterminate and borderline Quantiferon Gold TB IGRA results
Source: Eur Respir J, 50 (4) 1701267; 10.1183/13993003.01267-2017
Year: 2017
Discordance between tuberculin skin tests (TST) and interferon gamma release assays (IGRAs): Are we over-treating LTBI?
Source: International Congress 2018 – Tuberculosis transmission and screening strategies
Year: 2018
IGRA testing correlation with clinical and laboratory parameters in patients with tuberculosis
Source: Annual Congress 2011 - Risk assessment for tuberculosis
Year: 2011
Tuberculin skin test and IGRA test in the diagnosis and follow-up of bacteriologically confirmed pulmonary tuberculosis in HIV negative adults
Source: Annual Congress 2012 - Tuberculosis and immunologic assays
Year: 2012
Tuberculosis after a borderline QuantiFERON result during screening before infliximab
Source: Eur Respir J, 52 (2) 1800913; 10.1183/13993003.00913-2018
Year: 2018
Indeterminate results of the quantiFERON®TB gold (QFT) in hospitalized patients at risk for MTB infection/disease
Source: Annual Congress 2008 - Interferon-gamma release assay tests for diagnosing tuberculosis infection and disease
Year: 2008
High positive predictive value of Xpert in a low rifampicin resistance prevalence setting
Source: Eur Respir J 2014; 44: 1711-1713
Year: 2014
Predictive factors for a positive BAL Xpert MTB/RIF in BAL AFB smear negative PTB patients who are sputum scarce or AFB smear negative
Source: International Congress 2016 – Advances in tuberculosis diagnosis and monitoring of treatment
Year: 2016
Smoking is a strong independent risk factor for indeterminate and false negative IGRA results
Source: Annual Congress 2011 - What is new in tuberculosis immunodiagnosis?
Year: 2011
Evaluation of IP-10 in IGRA for LTBI diagnosis
Source: International Congress 2018 – Tuberculosis transmission and screening strategies
Year: 2018
Value of QFT-IT test for diagnosing latent TB infection in HIV+
Source: ISSN=ISSN 1810-6838, ISBN=, page=284
Year: 2007
Performance of quantiferon test in screening for latent tuberculous infection in rheumatoid arthritis patients undergoing anti-TNF therapy
Source: Annual Congress 2008 - New tests and methods to diagnose tuberculosis infection and disease and to monitor treatment
Year: 2008
Comparison of the accuracy of QuantiFERON TB gold in tube vs QuantiFERON-TB plus
Source: International Congress 2016 – Active and latent tuberculosis: biomarkers
Year: 2016
Comparation of QFT-GIT test and tubeculine skin test in patients with sarcoidosis
Source: Annual Congress 2008 - New tests and methods to diagnose tuberculosis infection and disease and to monitor treatment
Year: 2008
Variables responsible for tuberculin positivity of household contacts of sputum positive TB cases
Source: Annual Congress 2011 - Tuberculin skin tests, interferon-gamma release assays and beyond
Year: 2011
Evaluation of tuberculin responsiveness and booster effect in HIV negative chronic hemodialysis patients and compare of their results with standard skin anergy test
Source: Eur Respir J 2005; 26: Suppl. 49, 417s
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept